WEST PHARMACEUTICAL SERVICES (WST)
US9553061055 - Common Stock
ChartMill assigns a Buy % Consensus number of 82% to WST. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 408.44. This target is 10.93% above the current price.
WST was analyzed by 13 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about WST.
In the previous month the buy percentage consensus was at a similar level.
WST was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-02-16 | UBS | Maintains | Neutral -> Neutral |
| 2024-02-13 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-02-07 | Jefferies | Upgrade | Hold -> Buy |
| 2023-10-27 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2023-08-30 | Keybanc | Maintains | Overweight -> Overweight |
| 2023-08-21 | Keybanc | Maintains | Overweight -> Overweight |
| 2023-07-28 | Keybanc | Maintains | Overweight -> Overweight |
| 2023-07-17 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2023-06-16 | B of A Securities | Upgrade | Neutral -> Buy |
| 2023-04-11 | Stephens & Co. | Upgrade | Equal-Weight -> Overweight |
| 2023-02-17 | Keybanc | Maintains | Overweight |
| 2022-12-14 | Deutsche Bank | Initiate | Hold |
| 2022-12-02 | Keybanc | Maintains | Overweight |
| 2022-11-30 | UBS | Initiate | Neutral |
| 2022-10-28 | Keybanc | Maintains | Overweight |
| 2022-10-28 | B of A Securities | Downgrade | Buy -> Neutral |
| 2022-04-29 | Keybanc | Maintains | Overweight |
| 2021-07-30 | Keybanc | Maintains | Overweight |